Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.aurobindo.com | |
Market Cap | 23,666.06 Cr. | |
Enterprise Value(EV) | 22,282.31 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 36.03 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 11.21 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 435.68 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 0.93 | Calculated using Price: 403.90 |
Dividend Yield | 2.23 | Period Ending 2022-03 |
No. of Shares Subscribed | 58.59 Cr. | 585,938,609 Shares |
FaceValue | 1 | |
Company Profile | ||
Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment. |
1 Day |
|
-1.46% |
1 Week |
|
-2.97% |
1 Month |
|
-8.45% |
3 Month |
|
-27.62% |
6 Month |
|
-27.46% |
1 Year |
|
-39.76% |
2 Year |
|
-56.10% |
5 Year |
|
-33.25% |
10 Year |
|
+320.82% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 36.79 | 35.29 | 32.51 | 27.57 | 22.99 | 18.47 | 18.62 | 27.81 | 11.52 | |
Return on Capital Employed (%) | 27.18 | 27.18 | 27.35 | 24.92 | 22.72 | 17.97 | 18.79 | 30.33 | 12.82 | |
Return on Assets (%) | 13.95 | 14.03 | 14.13 | 14.44 | 13.07 | 10.00 | 10.39 | 17.34 | 7.99 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 3,750 | 5,156 | 7,287 | 9,372 | 11,680 | 13,891 | 16,825 | 21,930 | 24,576 | 25,528 | |
Non Curr. Liab. | 1,494 | 1,592 | 584 | 102 | 594 | 358 | 555 | 807 | 903 | 809 | |
Curr. Liab. | 4,220 | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 8,156 | 10,450 | |
Minority Int. | 26 | 26 | 3 | 2 | 2 | 2 | 0 | -1 | -2 | 13 | |
Equity & Liab. | 9,490 | 12,910 | 15,714 | 16,082 | 20,942 | 26,271 | 28,765 | 33,401 | 33,633 | 36,799 | |
Non Curr. Assets | 3,859 | 4,611 | 5,420 | 6,875 | 8,764 | 10,939 | 12,352 | 13,578 | 15,510 | 16,571 | |
Curr. Assets | 5,631 | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,824 | 18,123 | 20,228 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 9,490 | 12,910 | 15,714 | 16,082 | 20,942 | 26,271 | 28,765 | 33,401 | 33,633 | 36,799 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 8,100 | 12,121 | 13,795 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 23,787 | |
Other Income | 22 | 97 | 204 | 116 | 102 | 155 | 192 | 381 | 323 | 212 | |
Total Income | 8,121 | 12,217 | 13,998 | 15,025 | 16,565 | 19,719 | 23,290 | 25,155 | 23,778 | 23,999 | |
Total Expenditure | -5,966 | -9,557 | -10,607 | -11,475 | -12,691 | -15,612 | -18,234 | -19,441 | -19,071 | -20,069 | |
PBIDT | 2,155 | 2,660 | 3,392 | 3,550 | 3,874 | 4,107 | 5,056 | 5,714 | 4,707 | 3,930 | |
Interest | -310 | -160 | -257 | -67 | -78 | -263 | -305 | -74 | -49 | -65 | |
Depreciation | -313 | -333 | -392 | -428 | -558 | -668 | -967 | -1,055 | -1,127 | -1,130 | |
Taxation | -363 | -597 | -721 | -760 | -818 | -727 | -899 | -2,010 | -726 | -479 | |
Exceptional Items | -88 | -26 | 2,815 | -128 | -128 | ||||||
PAT | 1,169 | 1,571 | 2,022 | 2,296 | 2,420 | 2,362 | 2,859 | 5,389 | 2,678 | 2,128 | |
Minority Interest | 4 | 5 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | ||
Share Associate | 1 | 5 | 3 | 3 | -15 | -55 | -31 | -16 | |||
Other Related Items | |||||||||||
Consolidated Net Profit | 1,173 | 1,576 | 2,025 | 2,302 | 2,423 | 2,365 | 2,845 | 5,335 | 2,648 | 2,111 | |
Adjusted EPS | 20 | 27 | 35 | 39 | 41 | 40 | 49 | 91 | 45 | 36 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 275 | 646 | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | |
Cash Fr. Inv. | -246 | -819 | -1,398 | -1,445 | -1,787 | -1,927 | -2,903 | -1,568 | 599 | -3,212 | |
Cash Fr. Finan. | 108 | 118 | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | |
Net Change | 137 | -55 | -68 | 340 | -424 | 892 | 667 | 866 | 2,563 | -1,164 | |
Cash & Cash Eqvt | 203 | 148 | 461 | 744 | 320 | 1,210 | 1,876 | 2,747 | 5,330 | 4,163 |
Fri, 03 Feb 2023
Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. Further to our letter dated January 31 2023 intimating the date of Board Meeting to be held on February 9 2023 inter alia to consider unaudited financial results for the quarter and nine months period ended December 31 2022 and interim dividend for the FY 2022-23 and pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 we hereby inform that the interim dividend if declared shall be paid to the equity shareholders of the Company whose names appear on the Register of Members as on February 17 2023 which is the Record Date fixed for this purpose. |
Fri, 03 Feb 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the schedule of Earnings Call to be held on February 10 2023 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022. |
Tue, 31 Jan 2023
Board Meeting Intimation for Intimation Of Board Meeting AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday February 9 2023 to consider and approve inter alia the following:1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022 and2. Payment of Interim Dividend if any for the financial year 2022-23.Further to our letter dated December 29 2022 informing about the closure of Trading Window of the Company from January 1 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2022 we inform you that the Trading Window will remain closed up to February 11 2023 and shall be re-opened on February 12 2023. |
Fri, 03 Feb 2023 |
|
|
|
|
|